Stockscreener 앱 받기
6.60
1.35%
-0.09
시간 외 거래:
6.65
0.05
+0.76%
전일 마감가:
$6.69
열려 있는:
$6.69
하루 거래량:
1.07M
Relative Volume:
0.98
시가총액:
$465.87M
수익:
-
순이익/손실:
$-297.11M
주가수익비율:
-1.2717
EPS:
-5.19
순현금흐름:
$-216.95M
1주 성능:
+5.94%
1개월 성능:
+14.58%
6개월 성능:
-62.33%
1년 성능:
-37.85%
1일 변동 폭
$6.35
$6.89
1주일 범위
$6.025
$6.89
52주 변동 폭
$4.07
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
6.60 | 465.87M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Raymond James Financial Inc. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Charles Schwab Investment Management Inc. Has $2.87 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Bank of New York Mellon Corp Purchases 4,557 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Jefferies cuts Phathom Pharmaceuticals target to $13 By Investing.com - Investing.com UK
Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating - Marketscreener.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Average Price Target from Brokerages - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by Keybank National Association OH - Defense World
Phathom Pharmaceuticals stock hits 52-week low at $4.34 - Investing.com
Phathom Pharmaceuticals stock hits 52-week low at $4.34 By Investing.com - Investing.com Australia
Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Simply Wall St
Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group - Defense World
Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges - TipRanks
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Boosted by Rhumbline Advisers - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC Wainwright - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World
Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs - TipRanks
Phathom Pharmaceuticals price target lowered to $19 from $27 at Craig-Hallum - TipRanks
H.C. Wainwright maintains $28 target on Phathom Pharma stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $28 target on Phathom Pharma stock - Investing.com
Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating - TipRanks
Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... - Yahoo Finance
Phathom Pharmaceuticals Reports Strong Growth with VOQUEZNA - TipRanks
Phathom Pharmaceuticals: Strong Performance and Optimistic Outlook Amidst Patent Uncertainty - TipRanks
Stifel maintains Buy on Phathom stock with $28 target - Investing.com India
Stifel maintains Buy on Phathom stock with $28 target By Investing.com - Investing.com South Africa
Earnings call transcript: Phathom Pharma Q4 2024 sees 81% revenue rise - Investing.com UK
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result - GuruFocus.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 - Investing.com
Phathom Pharmaceuticals stock hits 52-week low at $5.21 By Investing.com - Investing.com Canada
(PHAT) Investment Analysis and Advice - Stock Traders Daily
Phathom Pharmaceuticals (PHAT) Expected to Announce Earnings on Thursday - MarketBeat
Cantor Fitzgerald Upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) to Strong-Buy - MarketBeat
Phathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on Thursday - Defense World
Phathom Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 - The Manila Times
Phathom Pharmaceuticals to Host Conference Call on March 6, 2025, for Fourth Quarter and Full Year 2024 Financial Results - Nasdaq
Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - StockTitan
How to Take Advantage of moves in (PHAT) - Stock Traders Daily
Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN
Cantor Fitzgerald Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Phathom spikes as Cantor Fitzgerald bullish on IP claims - MSN
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.34%
자본화:
|
볼륨(24시간):